Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin lung toxicity. Acute and chronic phases

S H Okuno1, S Frytak

  • 1Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.

American Journal of Clinical Oncology
|June 1, 1997
PubMed
Summary

Mitomycin C (MMC) can cause rare lung toxicity in non-small cell lung cancer (NSCLC) patients. This toxicity can progress to severe pulmonary insufficiency, even with corticosteroid treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Graft vs GIST?

Bone marrow transplantation·2012
Same author

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

Sarcoma·2008
Same author

Bizarre big belly ball: intraabdominal abscess mimicking stauffer syndrome secondary to uterine leiomyosarcoma.

European journal of gynaecological oncology·2007
Same author

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.

Gene therapy·2005

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Mitomycin C (MMC) is an antineoplastic agent used in cancer treatment.
  • Pulmonary toxicity is a known, albeit rare, side effect of MMC.
  • Non-small cell lung cancer (NSCLC) is a common indication for MMC-containing regimens.

Purpose of the Study:

  • To describe the clinical characteristics and outcomes of pulmonary toxicity associated with mitomycin C in NSCLC patients.
  • To highlight the underestimation of chronic, progressive pulmonary insufficiency as a sequela of MMC.

Main Methods:

  • Retrospective review of 14 cases of pulmonary toxicity from four clinical trials at The Mayo Clinic.
  • Analysis of patient charts treated with MMC for NSCLC between 1976 and 1995.
  • Inclusion of data on patient demographics, MMC dosage, treatment cycles, pulmonary function tests, and response to corticosteroids.

Main Results:

  • Median age of affected patients was 61 years; M:F ratio was 1:1.
  • Toxicity occurred at a median of four MMC cycles (range 2-5) with a median cumulative dose of 29 mg/m2.
  • Pulmonary function showed reduced diffusing lung capacity (DLCO) and PaO2; 40% experienced progressive insufficiency despite corticosteroids.

Conclusions:

  • Mitomycin C-induced pulmonary toxicity can lead to chronic, progressive pulmonary insufficiency.
  • This sequela is often underestimated and may not fully respond to standard corticosteroid treatment.
  • Further research is needed to understand and manage MMC-related lung injury in NSCLC patients.

Related Experiment Videos